|
Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, Shankar PS, Soderquist RS, Stein EM, Tingley JP, Winter PS, Zieser-Misenheimer EK, Alley HM, Yllanes A, Haney V, Blackwell KL, McCall SJ, McDonnell DP, Wood KC. "PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation." Sci Transl Med.;8(369):369ra175. PubMed |
|
Bayar MAmine, Ivanova A, Le Teuff G. "CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method." Comput Methods Programs Biomed.;176:211-223. PubMed |
|
Blackwell K, Donskih R, Jones M, Nixon A, Vidal MJ, Nakov R, Singh P, Schaffar G, Gascón P, Harbeck N. "A comparison of proposed biosimilar LA-EP2006 and reference Pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving Myelosuppressive adjuvant or Neoadjuvant chemotherapy: Pegfilgrastim Randomized Oncology (Supp" Oncologist.;21(7):789-94. PubMed |
|
Chen H, Zeng D, Wang Y. "Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression." Biometrics.;73(4):1343-1354. PubMed |
|
Chen X, Cai J. "Reweighted estimators for additive hazard model with censoring indicators missing at random." Lifetime Data Anal.;24(2):224-249. PubMed |
|
Chiuzan C, Shtaynberger J, Manji GA, Duong JK, Schwartz GK, Ivanova A, Lee SM. "Dose-finding designs for trials of molecularly targeted agents and immunotherapies." J Biopharm Stat.;27(3):477-494. PubMed |
|
Choi J, Zeng D, Olshan AF, Cai J. "Joint modeling of survival time and longitudinal outcomes with flexible random effects." Lifetime Data Anal.;24(1):126-152. PubMed |
|
Deng Y, Zeng D, Zhao J, Cai J. "Proportional hazards model with a change point for clustered event data." Biometrics.;73(3):835-845. PubMed |
|
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." Lancet Oncol.;18(6):732-742. PubMed |
|
Fan A, Song R, Lu W. "Change-plane analysis for subgroup detection and sample size calculation." J Am Stat Assoc.;112(518):769-778. PubMed |
|
Farber H, Tsvankin V, Narloch JL, Kim GJ, Salama AKS, Vlahovic G, Blackwell KL, Kirkpatrick JP, Fecci PE. "Embracing rejection: Immunologic trends in brain metastasis." Oncoimmunology.;5(7):e1172153. PubMed |
|
Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NYR, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. "Translational Breast Cancer Research Consortium (TBCRC) 022: A phase II trial of Neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases." J Clin Oncol.;34(9):945-52. PubMed |
|
Gao H, Kelsey CR, Boyle J, Xie T, Catalano S, Wang X, Yin FF. "Impact of esophageal motion on dosimetry and toxicity with thoracic radiation therapy." Technol Cancer Res Treat.;18:1533033819849073. PubMed |
|
Hamy AS, Tury S, Wang X, Gao J, Pierga JY, Giacchetti S, Brain E, Pistilli B, Marty M, Espié M, Benchimol G, Laas E, Laé M, Asselain B, Aouchiche B, Edelman M, Reyal F. "Celecoxib with neoadjuvant chemotherapy for breast cancer might worsen outcomes differentially by COX-2 expression and ER status: Exploratory analysis of the REMAGUS02 trial." J Clin Oncol.;37(8):624-635. PubMed |
|
Harbeck N, Lipatov O, Frolova M, Udovitsa D, Topuzov E, Ganea-Motan DElena, Nakov R, Singh P, Rudy A, Blackwell K. "Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Future Oncol.;12(11):1359-67. PubMed |
|
Ivanova A, Wang Y, Foster MC. "The rapid enrollment design for Phase I clinical trials." Stat Med.;35(15):2516-24. PubMed |
|
Jia X, Ivanova A, Lee SM. "Selection of the initial design for the two-stage continual reassessment method." J Biopharm Stat.;27(3):495-506. PubMed |
|
Jiang R, Lu W, Song R, Hudgens MG, Naprvavnik S. "Doubly robust estimation of optimal treatment regimes for survival data-with application to an HIV/AIDS study." Ann Appl Stat.;11(3):1763-1786. PubMed |
|
Jung SH. "Design of phase II non-inferiority trials." Contemp Clin Trials Commun.;7:23-27. PubMed |
|
Jung SH. "Phase II cancer clinical trials for biomarker-guided treatments." J Biopharm Stat.;28(2):256-263. PubMed |
|
Jung SH. "Phase II trials for heterogeneous patient populations with a time-to-event endpoint." Med Res Arch.;5(7). PubMed |
|
Jung SH. "Randomized phase II cancer clinical tirals. |
|
Kang S, Lu W, Liu M. "Efficient estimation for accelerated failure time model under case-cohort and nested case-control sampling." Biometrics.;73(1):114-123. PubMed |
|
Kang S, Lu W, Song R. "Subgroup detection and sample size calculation with proportional hazards regression for survival data." Stat Med.;36(29):4646-4659. PubMed |
|
Kwak M, Jung SH. "Optimal two-stage log-rank test for randomized phase II clinical trials." J Biopharm Stat.;27(4):639-658. PubMed |
|
Lee H, Hudgens MG, Cai J, Cole SR. "Marginal structural Cox models with case-cohort sampling." Stat Sin.;26(2):509-526. PubMed |
|
Liang B, Tong X, Zeng D, Wang Y. "Semiparametric regression analysis of repeated current status data." Stat Sin.;27(3):1079-1100. PubMed |
|
Liu Z, Song R, Zeng D, Zhang J. "Principal components adjusted variable screening." Comput Stat Data Anal.;110:134-144. PubMed |
|
Liu Y, Wang Y, Zeng D. "Sequential multiple assignment randomization trials with enrichment design." Biometrics.;73(2):378-390. PubMed |
|
Luo S, Song R, Styner M, Gilmore JH, Zhu H. "FSEM: Functional structural equation models for twin functional data." J Am Stat Assoc.;114(525):344-357. PubMed |
|
Milanzi E, Molenberghs G, Alonso A, Kenward MG, Verbeke G, Tsiatis AA, Davidian M. "Properties of estimators in exponential family settings with observation-based stopping rules." J Biom Biostat.;7(1). PubMed |
|
Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, Blackwell K, Soliman H, Kahan Z, Bonnefoi H, Squires M, Zhang Y, Deudon S, Shi MM, André F. "Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy." Breast Cancer Res.;19(1):18. PubMed |
|
Ni A, Cai J. "A regularized variable selection procedure in additive hazards model with stratified case-cohort design." Lifetime Data Anal.;24(3):443-463. PubMed |
|
Ou FS, Zeng D, Cai J. "Quantile regression models for current status data." J Stat Plan Inference.;178:112-127. PubMed |
|
Pan Y, Cai J, Kim S, Zhou H. "Regression analysis for secondary response variable in a case-cohort study." Biometrics.;74(3):1014-1022. PubMed |
|
Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AKishor, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE. "Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012." J Clin Oncol.;34(33):3992-3999. PubMed |
|
Parke T, Marchenko O, Anisimov V, Ivanova A, Jennison C, Perevozskaya I, Song G. "Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?" J Biopharm Stat.;27(3):457-476. PubMed |
|
Potthoff RF, Halabi S. "A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events." Pharm Stat.;14(4):273-83. PubMed |
|
Roe MT, Cyr DD, Eckart D, Schulte PJ, Morse MA, Blackwell KL, Ready NE, Zafar Y, Beaven AW, Strickler JH, Onken JE, Winters KJ, Houterloot L, Zamoryakhin D, Wiviott SD, White HD, Prabhakaran D, Fox KAA, Armstrong PW, Ohman M. "Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome." Eur Heart J.;37(4):412-22. PubMed |
|
Schild SE, Fan W, Stinchcombe TE, Vokes EE, Ramalingam SS, Bradley JD, Kelly K, Pang HH, Wang X. "Toxicity related to radiotherapy dose and targeting strategy: A pooled analysis of cooperative group trials of combined modality therapy for locally advanced non-small cell lung cancer." J Thorac Oncol.;14(2):298-303. PubMed |
|
Shi C, Song R, Lu W. "On testing conditional qualitative treatment effects." Ann Stat.;47(4):2348-2377. PubMed |
|
Shook-Sa BE, Chen DG, Zhou H. "Using structural equation modeling to assess the links between tobacco smoke exposure, volatile organic compounds, and respiratory function for adolescents aged 6 to 18 in the United States." Int J Environ Res Public Health.;14(10). PubMed |
|
Stinchcombe TE, Jänne PA, Wang X, Bertino EM, Weiss J, Bazhenova L, Gu L, Lau C, Paweletz C, Jaslowski A, Gerstner GJ, Baggstrom MQ, Graziano S, Bearden J, Vokes EE. "Effect of Erlotinib plus Bevacizumab vs Erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: A phase 2 randomized clinical trial. " JAMA Oncol.;5(10):1448-1455. PubMed |
|
Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X. "Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US National Cancer Institute Cooperative Group Studies." J Clin Oncol.;35(25):2885-2892. PubMed |
|
Su L, Lu W, Song R. "Modelling and estimation for optimal treatment decision with interference." Stat (Int Stat Inst).;8(1). PubMed |
|
Tan Z, Qin G, Zhou H. "Estimation of a partially linear additive model for data from an outcome-dependent sampling design with a continuous outcome." Biostatistics.;17(4):663-76. PubMed |
|
Wages NA, Ivanova A, Marchenko O. "Practical designs for Phase I combination studies in oncology." J Biopharm Stat.;26(1):150-66. PubMed |
|
Wang X, Zhou J, Wang T, George SL. "On enrichment strategies for biomarker stratified clinical trials." J Biopharm Stat.;28(2):292-308. PubMed |
|
Wang X, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Ganti AKishor, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H. "Validation of progression-free survival as a surrogate endpoint for overall survival in malignant mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials." Oncologist.;22(2):189-198. PubMed |
|
Xia F, George SL, Wang X. "A multi-state model for designing clinical trials for testing overall survival allowing for crossover after progression." Stat Biopharm Res.;8(1):12-21. PubMed |
|
Xiao W, Lu W, Zhang HHelen. "Joint structure selection and estimation in the time-varying coefficient Cox model. " Stat Sin.;26(2):547-567. PubMed |
|
Yan Y, Zhou H, Cai J. "Improving efficiency of parameter estimation in case-cohort studies with multivariate failure time data." Biometrics.;73(3):1042-1052. PubMed |
|
Yao XI, Wang X, Speicher PJ, Hwang S, Cheng P, Harpole DH, Berry MF, Schrag D, Pang HH. "Reporting and guidelines in propensity score analysis: A systematic review of cancer and cancer surgical studies." J Natl Cancer Inst.;109(8). PubMed |
|
Yu J, Liu Y, Cai J, Sandler DP, Zhou H. "Outcome-dependent sampling design and inference for Cox's proportional hazards model." J Stat Plan Inference.;178:24-36. PubMed |
|
Yuan J, Pang H, Tong T, Xi D, Guo W, Mesenbrink P. "Seamless phase IIa/IIb and enhanced dose-finding adaptive design." J Biopharm Stat.;26(5):912-23. PubMed |
|
Zhang J, Liang W, Liang H, Wang X, He J. "Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses." Ann Transl Med.;7(11):244. PubMed |
|
Zhao Y, Saville BR, Zhou H, Koch GG. "Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment." J Biopharm Stat.;26(2):269-79. PubMed |
|
Zhou Q, Zhou H, Cai J. "Case-cohort studies with interval-censored failure time data." Biometrika.;104(1):17-29. PubMed |
|
Zhou Q, Cai J, Zhou H. "Outcome-dependent sampling with interval-censored failure time data." Biometrics.;74(1):58-67. PubMed |
|
Zhu Z, Wang X, Saha-Chaudhuri P, Kosinski AS, George SL. "Time-dependent classification accuracy curve under marker-dependent sampling." Biom J.;58(4):974-92. PubMed |
|
Zou B, Zou F, Shuster JJ, Tighe PJ, Koch GG, Zhou H. "On variance estimate for covariate adjustment by propensity score analysis." Stat Med.;35(20):3537-48. PubMed |
